Hepatitis C virus (HCV) infections are associated with the risk of progression to fibrosis, cirrhosis, and hepatocellular carcinoma. The HCV RNA genome is translated by an internal ribosome entry site ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted marketing authorization for Cepheid’s Xpert HCV test and GeneXpert Xpress System, the first ...
Maternal hepatitis C virus (HCV) RNA titer > 10⁶ International Units (IU)/mL and antepartum bleeding are key predictors of perinatal transmission, with the risk ranging from 1.5% to 28.5%. The ...
A new rapid test for hepatitis C could help identify many more patients who could be cured of the deadly disease, but its use may be limited unless insurers' reimbursement rises to cover its high cost ...
Fluctuations in circulating hepatitis C virus RNA could be "clinically meaningful" in a substantial number of patients with chronic infection, and could influence the best time to prescribe antiviral ...
Please provide your email address to receive an email when new articles are posted on . The FDA’s recent authorization of a rapid, point-of-care test to diagnose current hepatitis C virus infection is ...
Credit: Cepheid. The Xpert HCV test delivers results in about an hour. The Food and Drug Administration (FDA) has granted marketing authorization to Xpert ® HCV, a point-of-care hepatitis C virus (HCV ...
The FDA has greenlit its first point-of-care diagnostic test for hepatitis C, capable of using only a fingerstick blood sample, in a bid to quickly connect patients with antiviral drugs. “Despite the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback